Cerulean Pharma (CERU) Reaches $0.33 52-Week Low; Pricesmart (PSMT)’s Sentiment Is 1.16

June 19, 2017 - By Stephen Andrade

The stock of Cerulean Pharma Inc (NASDAQ:CERU) hit a new 52-week low and has $0.31 target or 5.00% below today’s $0.33 share price. The 6 months bearish chart indicates high risk for the $9.21 million company. The 1-year low was reported on Jun, 19 by Barchart.com. If the $0.31 price target is reached, the company will be worth $460,500 less. About 161,806 shares traded. Cerulean Pharma Inc (NASDAQ:CERU) has declined 82.21% since June 19, 2016 and is downtrending. It has underperformed by 98.91% the S&P500.

PriceSmart, Inc., through its subsidiaries, is engaged in the international operation of membership shopping in warehouse clubs. The company has market cap of $2.52 billion. In addition, the Company operates distribution centers and offices in the United States. It has a 28.78 P/E ratio. The Company’s divisions include the United States, Central America, the Caribbean and Colombia.

Cerulean Pharma Inc. is a clinical-stage, oncology-focused company. The company has market cap of $9.21 million. The Firm applies its Dynamic Tumor Targeting platform to develop differentiated therapies. It currently has negative earnings. The Company’s platform utilizes nanoparticle-drug conjugates , which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads.

Among 7 analysts covering Cerulean Pharmaceuticals (NASDAQ:CERU), 3 have Buy rating, 0 Sell and 4 Hold. Therefore 43% are positive. Cerulean Pharmaceuticals has $16 highest and $1 lowest target. $6’s average target is 1712.69% above currents $0.331 stock price. Cerulean Pharmaceuticals had 12 analyst reports since August 7, 2015 according to SRatingsIntel. JMP Securities downgraded the stock to “Market Perform” rating in Thursday, August 18 report. The company was initiated on Friday, August 28 by TH Capital. As per Thursday, August 18, the company rating was downgraded by Janney Capital. As per Wednesday, January 6, the company rating was initiated by Janney Capital. Roth Capital initiated Cerulean Pharma Inc (NASDAQ:CERU) rating on Friday, August 28. Roth Capital has “Buy” rating and $9 target. The firm has “Overweight” rating given on Tuesday, August 30 by Barclays Capital. Barclays Capital initiated Cerulean Pharma Inc (NASDAQ:CERU) rating on Tuesday, September 22. Barclays Capital has “Overweight” rating and $8 target. The stock of Cerulean Pharma Inc (NASDAQ:CERU) has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. The company was downgraded on Thursday, August 18 by Leerink Swann. The rating was downgraded by Wedbush to “Neutral” on Thursday, August 18.

Investors sentiment increased to 1.33 in Q4 2016. Its up 0.77, from 0.56 in 2016Q3. It improved, as 5 investors sold Cerulean Pharma Inc shares while 4 reduced holdings. 5 funds opened positions while 7 raised stakes. 5.25 million shares or 16.37% less from 6.28 million shares in 2016Q3 were reported. Manufacturers Life Insur Co The holds 0% or 193 shares in its portfolio. Vanguard Group Inc invested in 0% or 501,608 shares. Commercial Bank Of America De stated it has 7,000 shares. Brown Advisory stated it has 0% in Cerulean Pharma Inc (NASDAQ:CERU). Art Advisors Limited Com holds 0% of its portfolio in Cerulean Pharma Inc (NASDAQ:CERU) for 59,300 shares. Goldman Sachs Group holds 0% or 33,883 shares. 40,656 were reported by Oxford Asset Mgmt. Kcg Inc holds 0% or 23,535 shares in its portfolio. Renaissance Technologies holds 53,100 shares. Savings Bank Of Montreal Can owns 120 shares. 13,066 are held by Northern Tru Corporation. Walleye Trading Ltd Liability Com holds 0% of its portfolio in Cerulean Pharma Inc (NASDAQ:CERU) for 1,300 shares. Geode Capital Mgmt Limited Liability Corporation, Massachusetts-based fund reported 88,917 shares. Rock Springs Mngmt Lp owns 0.03% invested in Cerulean Pharma Inc (NASDAQ:CERU) for 625,000 shares. Tower Rech Ltd Liability Co (Trc) invested in 6,932 shares or 0% of the stock.

Sandhill Capital Partners Llc holds 2.58% of its portfolio in PriceSmart, Inc. for 112,597 shares. Pecaut & Co. owns 20,940 shares or 1.69% of their US portfolio. Moreover, Kayne Anderson Rudnick Investment Management Llc has 1.09% invested in the company for 1.10 million shares. The Virginia-based London Co Of Virginia has invested 0.83% in the stock. Genesis Asset Managers Llp, a United Kingdom-based fund reported 168,122 shares.

About 64,326 shares traded. PriceSmart, Inc. (PSMT) has risen 3.40% since June 19, 2016 and is uptrending. It has underperformed by 13.30% the S&P500.

Analysts await PriceSmart, Inc. (NASDAQ:PSMT) to report earnings on July, 6. They expect $0.69 EPS, up 25.45% or $0.14 from last year’s $0.55 per share. PSMT’s profit will be $20.18M for 31.21 P/E if the $0.69 EPS becomes a reality. After $0.90 actual EPS reported by PriceSmart, Inc. for the previous quarter, Wall Street now forecasts -23.33% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: